Precision Optics Corporation Inc. (POCI)
POCI trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/867840/000168316826007462/0001683168-26-007462-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | POCI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000867840 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | MA |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $31.5M |
| Net income | -$3.6M |
| Operating income | -$3.5M |
| Net margin | -11.5% |
| Operating margin | -11.1% |
| Revenue growth | +65.2% |
| Cash | $9.8M |
| Total assets | $32.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-K 2026-09-28 |
| Cash and burn | $9.8M cash; operating cash flow -$388K a quarter. | Report 2026-06-30 |
| Shares outstanding | 10,972,792 (2026-09-20); 7,714,701 a year earlier; 6,066,518 three years earlier. | Cover page 2026-09-20 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-03-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Stowe & Degon LLC, Westborough, Massachusetts, United States | PCAOB Form AP 2026-10-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $230K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | $8.8M | -$104K | -$649K | $9.8M | $1.3M | $31.5M | 10-K 2026-09-28 |
| Q3 2026 2026-03-31 | $8.7M | -$108K | -$723K | $10.7M | $1.5M | $28.9M | 10-Q 2026-05-13 |
| Q2 2026 2025-12-31 | $7.4M | -$1.8M | -$256K | $881K | $1.6M | $24.4M | 10-Q 2026-02-17 |
| Q1 2026 2025-09-30 | $6.7M | -$1.6M | $78K | $1.4M | $1.8M | $21.6M | 10-Q 2025-11-13 |
| Q4 2025 2025-06-30 | $6.2M | -$1.4M | -$418K | $1.8M | $1.9M | $19.1M | 10-K 2026-09-28 |
| Q3 2025 2025-03-31 | $4.2M | -$2.1M | -$1.9M | $2.5M | $2.1M | $17.6M | 10-Q 2026-05-13 |
| Q2 2025 2024-12-31 | $4.5M | -$970K | -$787K | $212K | $2.1M | $18.7M | 10-Q 2026-02-17 |
| Q1 2025 2024-09-30 | $4.2M | -$1.3M | -$319K | $636K | $2.1M | $19.0M | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 424B5 PROSPECTUS SUPPLEMENT | 424B5 | 2026-03-30 |
| Latest annual report FORM 10-K FOR JUNE 2026 | 10-K | 2026-09-28 |
| Latest quarterly / interim FORM 10-Q FOR SEP 2026 | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-16 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-10-27 |
Source: SEC EDGAR submissions feed, 807 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.0% |
| 1 month | +14.7% |
| 3 months | +24.5% |
| Year to date | +24.8% |
| 1 year | +8.3% |
| From 52-week high | -12.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| QTI | QT Imaging Holdings Inc. | $1.80 | -4.26% | $26.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier